Prevent hearing damage during cisplatin chemotherapy
Part of Brain & nervous system, Ear, nose & throat clinical trials.
This Phase 2 trial tests whether sodium thiosulfate and mannitol can reduce hearing damage (ototoxicity) in adults receiving cisplatin chemotherapy. It may help protect hearing while you get cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and starting cisplatin chemotherapy as part of your cancer care
- You can sign consent and follow the study plan
- Your general function is good (ECOG 0 to 2, meaning you are able to do most daily activities)
- If you can become pregnant: you must have a negative pregnancy test and agree to reliable birth control during the study
- Your kidney function is not significantly reduced (creatinine clearance 60 mL/min or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how cisplatin chemotherapy affects hearing and balance in people with head and neck cancer. It compares those getting cisplatin-based treatment to those getting only radiation. The goal is to better understand and potentially reduce these side effects.
This study looks at how cisplatin chemotherapy affects the kidneys. It may help doctors better predict and protect against kidney damage when patients start cisplatin.
This trial tests whether a medicine called sodium thiosulfate can protect your hearing from the side effects of cisplatin chemotherapy. It is for people with newly diagnosed cancer who are about to receive cisplatin for the first time.
This trial tests whether a gel placed in the ear can protect against hearing loss caused by high-dose cisplatin chemotherapy. It is for people with head and neck cancer who are scheduled to receive a certain amount of cisplatin.
This trial tests if taking N-acetylcysteine (NAC) can help prevent hearing loss caused by high-dose cisplatin chemotherapy. If you're getting cisplatin and are between 18 and 70, you may be able to join.
This trial tests whether adding Pedmark (sodium thiosulfate) to cisplatin chemotherapy can protect hearing in men with stage II or III testicular germ cell tumors. It aims to reduce the risk of drug-related ear damage while still treating the cancer.
Hear when a new Ototoxic Hearing Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.